ACUR insider filings

ACURA PHARMACEUTICALS, INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-01-15. Screen ACUR transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ACUR between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — ACURA PHARMACEUTICALS, INC

FiledFormInsiderReported transactionsSource
2026-01-154THANGARAJ IMMANUEL — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2026-01-154ROSS GEORGE K — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2026-01-154SKELLY WILLIAM G — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2025-02-044THANGARAJ IMMANUEL — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2025-01-244ROSS GEORGE K — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2025-01-244SKELLY WILLIAM G — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2024-01-024THANGARAJ IMMANUEL — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2024-01-024ROSS GEORGE K — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2024-01-024SKELLY WILLIAM G — DirectorOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2024-01-024WESSON BRUCE F — DirectorOption exercise (M): 37,500 · Option exercise (M): 37,500 (derivative) · Disposition to issuer (D): 12,500 (derivative)EDGAR
2023-11-204Brzeczko Albert W — See RemarksOption exercise (M): 40,000 · Option exercise (M): 40,000 (derivative)EDGAR
2023-11-204Jones Robert B — President & CEOOption exercise (M): 40,000 · Option exercise (M): 40,000 (derivative)EDGAR
2023-11-204Seiser Robert A — VP, Treasurer & ControllerOption exercise (M): 40,000 · Option exercise (M): 40,000 (derivative)EDGAR
2023-11-204CLEMENS PETER A — Senior VP & CFOOption exercise (M): 40,000 · Option exercise (M): 40,000 (derivative)EDGAR
2023-01-054Brzeczko Albert W — See RemarkOption exercise (M): 34,000 · Option exercise (M): 34,000 (derivative)EDGAR
2023-01-054Jones Robert B — President & CEOOption exercise (M): 50,000 · Option exercise (M): 50,000 (derivative)EDGAR
2023-01-054Seiser Robert A — VP, Treasurer & ControllerOption exercise (M): 20,000 · Option exercise (M): 20,000 (derivative)EDGAR
2023-01-054THANGARAJ IMMANUEL — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2023-01-054ROSS GEORGE K — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2023-01-054SKELLY WILLIAM G — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2023-01-054WESSON BRUCE F — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative)EDGAR
2023-01-054CLEMENS PETER A — Senior VP & CFOOption exercise (M): 40,000 · Option exercise (M): 40,000 (derivative)EDGAR
2022-08-054Brzeczko Albert W — VP, Pharma Sciences - APTOption exercise (M): 43,333 · Option exercise (M): 9,333 (derivative) · Option exercise (M): 34,000 (derivative)EDGAR
2022-08-054Jones Robert B — President & CEOOption exercise (M): 63,666 · Option exercise (M): 13,666 (derivative) · Option exercise (M): 50,000 (derivative)EDGAR
2022-08-054Seiser Robert A — VP, Controller & TreasurerOption exercise (M): 24,666 · Option exercise (M): 4,666 (derivative) · Option exercise (M): 20,000 (derivative)EDGAR
2022-08-054CLEMENS PETER A — Senior VP & CFOOption exercise (M): 49,333 · Option exercise (M): 9,333 (derivative) · Option exercise (M): 40,000 (derivative)EDGAR
2022-03-184Brzeczko Albert W — VP, Pharma Sciences - APTGrant/award (A): 40,000 (derivative)EDGAR
2022-03-184Jones Robert B — President & CEOGrant/award (A): 40,000 (derivative)EDGAR
2022-03-184Seiser Robert A — VP, Controller & TreasurerGrant/award (A): 40,000 (derivative)EDGAR
2022-03-184CLEMENS PETER A — Senior VP & CFOGrant/award (A): 40,000 (derivative)EDGAR
2022-01-124THANGARAJ IMMANUEL — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative)EDGAR
2022-01-114WESSON BRUCE F — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative)EDGAR
2022-01-104ROSS GEORGE K — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative)EDGAR
2022-01-054SKELLY WILLIAM G — DirectorOption exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative)EDGAR
2021-06-284Abuse Deterrent Pharma, LLC — 10% ownerConversion (C): 42,984,375 @ $0.16 · Conversion (C): 6,877,500 (derivative) @ $0EDGAR
2021-06-284Schutte John — 10% ownerConversion (C): 42,984,375 @ $0.16 · Conversion (C) @ $0EDGAR
2021-05-284THANGARAJ IMMANUEL — DirectorGrant/award (A): 66,666 (derivative)EDGAR
2021-05-284ROSS GEORGE K — DirectorGrant/award (A): 66,666 (derivative)EDGAR
2021-05-284SKELLY WILLIAM G — DirectorGrant/award (A): 66,666 (derivative)EDGAR
2021-05-284WESSON BRUCE F — DirectorGrant/award (A): 66,666 (derivative)EDGAR
2021-02-264Seiser Robert A — VP, Treasurer & ControllerOption exercise (M): 20,000 @ $0.15 · Tax withholding (F): 7,550 @ $0.40 · Option exercise (M): 20,000 (derivative)EDGAR
2021-02-264EMIGH JAMES F — VP, Corporate DevelopmentOption exercise (M): 20,000 @ $0.15 · Tax withholding (F): 7,550 @ $0.40 · Option exercise (M): 20,000 (derivative)EDGAR
2021-02-264CLEMENS PETER A — Senior VP & CFOOption exercise (M): 40,000 @ $0.15 · Tax withholding (F): 15,100 @ $0.40 · Option exercise (M): 40,000 (derivative)EDGAR
2021-01-124THANGARAJ IMMANUEL — DirectorOption exercise (M): 54,790 · Option exercise (M): 54,790 (derivative)EDGAR
2021-01-064Seiser Robert A — VP, Treasurer & ControllerOption exercise (M): 24,667 · Tax withholding (F): 10,686 @ $0.21 · Option exercise (M): 4,667 (derivative) · Option exercise (M): 20,000 (derivative)EDGAR
2021-01-064EMIGH JAMES F — VP, Corporate DevelopmentOption exercise (M): 24,667 · Tax withholding (F): 7,402 @ $0.21 · Option exercise (M): 4,667 (derivative) · Option exercise (M): 20,000 (derivative)EDGAR
2021-01-064ROSS GEORGE K — DirectorOption exercise (M): 54,790 · Option exercise (M): 54,790 (derivative)EDGAR
2021-01-064SKELLY WILLIAM G — DirectorOption exercise (M): 54,790 · Option exercise (M): 54,790 (derivative)EDGAR
2021-01-064WESSON BRUCE F — DirectorOption exercise (M): 54,790 · Option exercise (M): 54,790 (derivative)EDGAR
2021-01-064CLEMENS PETER A — Senior VP & CFOOption exercise (M): 49,334 · Tax withholding (F): 19,514 @ $0.21 · Option exercise (M): 9,334 (derivative) · Option exercise (M): 40,000 (derivative)EDGAR

Recent 8-K events — ACURA PHARMACEUTICALS, INC

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-038-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-068-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-208-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-248-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-298-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-078-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-108-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-208-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-298-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2025-10-248-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ACUR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs